158 related articles for article (PubMed ID: 1473361)
1. Comparative in vitro activity of cefepime and four extended-spectrum beta-lactams on 1,251 aminoglycoside-resistant gram-negative hospital strains.
Vanhoof R; Nulens E; Nyssen HJ; Hannecart-Pokorni E
Chemotherapy; 1992; 38(4):225-31. PubMed ID: 1473361
[TBL] [Abstract][Full Text] [Related]
2. Gram-negative bacilli resistant to third-generation cephalosporins: beta-lactamase characterization and susceptibility to Sch 34343.
Medeiros AA; Hare R; Papa E; Adam C; Miller GH
J Antimicrob Chemother; 1985 Jun; 15 Suppl C():119-32. PubMed ID: 3875602
[TBL] [Abstract][Full Text] [Related]
3. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
Jones RN; Salazar JC; Pfaller MA; Doern GV
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984
[TBL] [Abstract][Full Text] [Related]
4. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
[TBL] [Abstract][Full Text] [Related]
5. Belgian multicentre study on the in vitro activity of cefepime against gram-negative bacilli.
Verbist L; Glupczynski Y
Acta Clin Belg; 1996; 51(1):28-35. PubMed ID: 8669160
[TBL] [Abstract][Full Text] [Related]
6. [Comparative in vitro activity of 2 monobactams (RO 172301 (AMA 1080)and aztreonam), ceftazidime and cefotaxime on Gram-negative bacilli].
Thabaut A; Meyran M; Huerre M
Pathol Biol (Paris); 1985 May; 33(5):404-7. PubMed ID: 3929217
[TBL] [Abstract][Full Text] [Related]
7. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.
Fung-Tomc J; Dougherty TJ; DeOrio FJ; Simich-Jacobson V; Kessler RE
Antimicrob Agents Chemother; 1989 Apr; 33(4):498-502. PubMed ID: 2499250
[TBL] [Abstract][Full Text] [Related]
8. In vitro activities of cefepime alone and with amikacin against aminoglycoside-resistant gram-negative bacteria.
Fung-Tomc J; Huczko E; Kolek B; Thater C; Kessler RE
Antimicrob Agents Chemother; 1991 Dec; 35(12):2652-4. PubMed ID: 1810203
[TBL] [Abstract][Full Text] [Related]
9. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
Baltch AL; Smith RP; Ritz W
Chemotherapy; 1994; 40(6):391-8. PubMed ID: 7842822
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
11. Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime.
Washington JA; Jones RN; Gerlach EH; Murray PR; Allen SD; Knapp CC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1696-700. PubMed ID: 8215286
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro evaluation of BMY-28142, a new broad-spectrum cephalosporin, versus other beta-lactams against multiresistant gram-negative isolates.
Giamarellou H; Sahin A; Chryssouli Z
Drugs Exp Clin Res; 1987; 13(3):149-53. PubMed ID: 3622243
[TBL] [Abstract][Full Text] [Related]
13. Cross-susceptibility of cefpirome and four other beta-lactams against isolates from haematology/oncology and intensive care units. International Study Group.
Spencer RC
Scand J Infect Dis Suppl; 1993; 91():25-32. PubMed ID: 8290900
[TBL] [Abstract][Full Text] [Related]
14. The activity of ceftazidime compared with those of aztreonam, newer cephalosporins and Sch 29482 against nonfermentative gram-negative bacilli.
Schell RF; Francisco M; Bihl JA; LeFrock JL
Chemotherapy; 1985; 31(3):181-90. PubMed ID: 3888543
[TBL] [Abstract][Full Text] [Related]
15. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
[TBL] [Abstract][Full Text] [Related]
16. [Antibacterial activity of carumonam and cefpirome on hospital strains resistant to gentamicin and cephalothin: comparison with other beta-lactam antibiotics, new fluoroquinolones, aminoglycosides and other antibiotics].
Vanhoof R; Nyssen HJ; Nulens E; Roebben E; Hubrechts JM
Pathol Biol (Paris); 1990 Jun; 38(6):634-7. PubMed ID: 2165238
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial resistance among gram-negative bacilli to newer aminoglycosides and beta-lactams.
Jain S; Sarkar R
Indian J Pathol Microbiol; 1991 Oct; 34(4):280-7. PubMed ID: 1818033
[TBL] [Abstract][Full Text] [Related]
18. [In-vitro activity of ceftriaxone on Gram-negative bacilli with various resistance phenotypes to cephalosporins. Comparison with cefotaxime, cefmenoxime, moxalactam, ceftazidime].
Rouhan D; Le Noc P; Le Noc D
Pathol Biol (Paris); 1986 May; 34(5):404-9. PubMed ID: 3534713
[TBL] [Abstract][Full Text] [Related]
19. Plasmid-mediated beta-lactamases among aminoglycoside resistant gram-negative bacilli.
Huovinen S; Klossner ML; Katila ML; Huovinen P
Scand J Infect Dis; 1989; 21(3):303-9. PubMed ID: 2667097
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of imipenem and six other beta-lactam antibiotics against aminoglycoside resistant gram-negative bacilli.
Bujdáková H; Kallová J; Lausová A; Kettner M
Microbios; 1995; 84(339):87-90. PubMed ID: 8628124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
